Search Results for “AI” – Page 2 – media

AI+Gene Therapy | Dyno partners with Roche, with a prepayment of $50 million and a total value exceeding $1 billion

On October 24, 2024, Dyno Therapeutics, a gene technology company that utilizes artificial intelligence for in vivo gene delivery, announced its second research collaboration with Roche to jointly develop the next generation of adeno-associated virus (AAV) vectors for gene therapy targeting neurological diseases.Dyno and Roche previously announced a research collaboration and licensing agreement in October 2020 for neurological disorders and liver targeted therapies. According to this new collaboration agreement, Dyno Therapeutics will provide Roche with more opportunities to utilize the company’s leading platform and sequence design technology in the field to achieve in vivo gene delivery. The existing gene therapies mainly use a small amount of naturally occurring AAV vectors, which have problems such as low delivery efficiency, pre-existing immunity, and manufacturability. To overcome these challenges, Dyno took the lead in applying artificial intelligence and high-throughput in vivo data acquisition technology to engineer the AAV virus capsid, in order to ...
- Source: drugdu
- 54
- November 1, 2024
brain-computer interface only costs $5,000

In reality, the brain-computer interface is connected to your brain at one end, extracting your ideas from the dense and complex neuronal electrical signals, and connected to external devices such as computers or machinery at the other end, directly bypassing your body to turn ideas into control signals and further execute commands. It does not need to rely on the peripheral nerves and muscle systems of your limbs to directly establish direct information exchange between the brain center and external devices. Musk released a monkey for experiment in 2021. The monkey typed a line of words “I want to eat snacks” on the computer through mind operation. This is supported by brain-computer interface technology. The cochlear implant that helps the disabled to obtain sound is the most successful and most popular technology for brain-computer interface so far. Its principle is to convert sound signals into electrical signals and transmit them ...
- Source: drugdu
- 51
- November 1, 2024
the wind rises, accelerates, and accelerates again

The development story of tumor drugs is always so similar: the early stage may be endless suffering, but after countless failures and dashed hopes, once there is a breakthrough, the progress is often unexpected. This is the development of drugs for the treatment of small cell carcinoma (SCLC). SCLC was first discovered about 100 years ago, but it was not until 1968 that the medical community discovered its neuroendocrine origin and finally clearly distinguished it from other lung cancers. In the 1980s, the treatment of platinum-containing chemotherapy combined with chest radiotherapy gradually became clear and became the basic treatment for small cell lung cancer. Although the combination of etoposide and carboplatin/cisplatin (EP) has been the standard treatment for SCLC until now; but we can also clearly see that the battle against small cell lung cancer has entered an accelerated stage. In May of this year, Amgen’s DLL3/CD3 dual antibody Tarlatamab ...
- Source: drugdu
- 56
- November 1, 2024
The hearing aid industry has a huge gap

In the current Chinese medical device industry, competition is extremely fierce, and many fields have become saturated, making it difficult to find new growth points or development space. But this set of data shows that there is a huge resource gap in the intervention of hearing loss in the elderly population in China. According to the “China Elderly Hearing Loss and Hearing Aid Application Survey” released by Tmall Health, Beijing Hearing Association, and Sonova Group, there is one professional hearing service provider for every 90000 people in China, which is much lower than the United States (9000:1). This huge gap not only reflects the scarcity of human resources allocation in this field in China, but also reflects the large scale of the population with hearing loss. 1. There are 120 million elderly people with hearing loss, and the wearing rate of hearing aids is less than 5% Hearing loss is ...
- Source: drugdu
- 60
- October 31, 2024
Continuously Advancing Digital Marketing for Attenuated Live Vaccines Against Shingles

On October 28, Baike Biology (688276) held a performance briefing for the third quarter of 2024. The company’s board members, including General Manager Kong Wei, Executive Deputy General Manager Jiang Chunlai, and Board Secretary Zhang Zhe, communicated with investors regarding the operating results and financial status for the third quarter of 2024. Baike Biology is an innovative biopharmaceutical company mainly focused on infectious disease prevention and control. Since its establishment, it has primarily engaged in the research, development, production, and sale of human vaccines. The company currently has approved vaccines, including chickenpox vaccines, intranasal flu vaccines, and shingles vaccines. Among these, the chickenpox vaccine has maintained a leading market share for many years, making it one of the company’s primary sources of revenue. The intranasal flu vaccine is a part of the World Health Organization’s (WHO) Global Influenza Action Plan (GAP) and is the only attenuated live influenza vaccine administered ...
- Source: drugdu
- 71
- October 30, 2024
Are stem cells the “terminator” of diabetes? Chinese scientists used stem cell regeneration therapy to cure type 1 diabetes for the first time

Cell, an international authoritative scientific journal, recently published a pioneering achievement from multiple research teams in China – the first time to use stem cell regeneration therapy to functionally cure type 1 diabetes. The research team used chemical reprogramming technology to induce pluripotent stem cells to prepare islet cells, and transplanted them to a type 1 diabetes patient, achieving clinical functional cure effect. So, how is it successful to induce stem cells to prepare pancreatic islet cells? Is functional cure truly a cure? Will stem cell technology be the key to conquer diabetes in the future? What is the difference between functional cure and cure Diabetes is a thorny disease, and its biggest harm to patients is that there are many clinical complications, which may lead to cardiovascular disease, nervous system damage, kidney disease, eye disease, foot disease, and so on. Diabetes ranks ninth among the world’s ten leading ...
- Source: drugdu
- 96
- October 28, 2024
AI+macrocyclic drug development | Circle Pharma completes $90 million Series D financing

On September 3, 2024, Circle Pharma, a biopharmaceutical company dedicated to discovering and developing cell permeable macrocycles as a clinical stage of a new therapy, announced the successful completion of $90 million in Series D funding, including the conversion of a convertible note.This round of financing is led by The Column Group, with new and old investors including Nextech Invest and Euclidean Capital participating. The funds raised from the financing will be used for the clinical development of Circle Pharma’s first and only similar cyclin A/B RxL inhibitor CID-078, and to support the development of the discovery project portfolio established by the company using its MXMO macrocycle platform. David Earp, CEO and Juris Doctor of Circle Pharma, said, “We are very grateful for the continued support of such a strong investor as we advance our pioneering work on macrocyclic therapy. This financing not only allows us to advance the clinical ...
- Source: drugdu
- 90
- October 28, 2024
Heyuan Biotechnology Reports 34.22% Revenue Growth in the First Three Quarters; Performance Outlook Remains Positive

On the evening of October 23, Heyuan Biotechnology released its third-quarter report for 2024. In the third quarter, the company achieved a revenue of 70.81 million yuan, a year-on-year increase of 32.99%, but realized a net profit attributable to shareholders of -76.42 million yuan. For the first three quarters of this year, the company recorded a total revenue of 184 million yuan, marking a year-on-year growth of 34.22%, with a net profit attributable to shareholders of -190 million yuan. Improved Industry Environment Provides Growth Opportunities According to public data, Heyuan Biotechnology’s main business includes providing Contract Research Organization (CRO) services such as the development of gene therapy vectors and gene function research for cellular and gene therapy foundational research. It also offers Contract Development and Manufacturing Organization (CDMO) services, including application for Investigational New Drug-Chemistry, Manufacturing, and Controls (IND-CMC) pharmaceutical research and GMP production of clinical samples for the development ...
- Source: drugdu
- 57
- October 26, 2024
Approval Notification for Supplementary Application of Sodium Oligosialic Acid Tetrahexosyl Ganglioside Injection

On October 23, Sai Sheng Pharmaceutical (300485) announced that it recently received an Approval Notification for the Supplementary Application of Sodium Oligosialic Acid Tetrahexosyl Ganglioside Injection issued by the National Medical Products Administration (NMPA). According to company regulations, the firm completed confirmatory clinical trials meeting current requirements within three years and submitted a supplementary application to the NMPA Center for Drug Evaluation, successfully obtaining the approval. The product’s labeling has been updated, indicating that the revised indication is for patients with acute ischemic stroke. The announcement stated that the Sodium Oligosialic Acid Tetrahexosyl Ganglioside Injection, available in specifications of 2ml:20mg, 2ml:40mg, and 5ml:100mg, has received the approval notification for the supplementary application. This will enhance the drug’s potential market sales and competitiveness in the future. However, due to the high-tech and high-risk nature of pharmaceutical products, sales performance may be influenced by national policies, changes in the market environment, and ...
- Source: drugdu
- 54
- October 26, 2024
Baiyu Pharmaceutical announces exclusive licensing agreement with Novartis for a small molecule anti-tumor drug

On October 17th, Baiyu Pharmaceutical announced an exclusive licensing agreement with Novartis for a small molecule anti-tumor drug. According to the agreement, Baiyu will receive a down payment of 70 million US dollars (approximately 499 million yuan), as well as various milestone payments and corresponding royalties for development, registration, and commercialization up to 1.1 billion US dollars (approximately 7.8 billion yuan). Novartis will obtain exclusive global development and commercialization rights for this small molecule innovative drug. Founded in 2005, Baiyu Pharmaceutical is headquartered in Chengdu, Sichuan. It is a global pharmaceutical enterprise with innovative drugs as its core, integrating research and development, production, sales, and traditional Chinese medicine cultivation into a full industry chain group. 10 pipelines under research, 5 tumor pipelines According to the announcement, the asset of this transaction is a small molecule innovative drug for the treatment of malignant tumors invented and discovered by the Baiyu Innovative ...
- Source: drugdu
- 67
- October 25, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.